^
10ms
A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315. (PubMed, Cancer Discov)
This agent shows promise in CCNE1-amplified cancers and in CDK4/6 inhibitor-resistant breast cancers. See related article by Dietrich et al., p. 446 (8).
Journal
|
CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2)
|
CCNE1 amplification
|
INX-315
1year
INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. (PubMed, Cancer Discov)
Using cell-based assays, patient-derived xenografts, and transgenic mouse models, we show that INX-315 (i) promotes retinoblastoma protein hypo-phosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, leading to durable control of tumor growth; (ii) overcomes breast cancer resistance to CDK4/6i, restoring cell cycle control whilst re-instating the chromatin architecture of CDK4/6i-induced TIS; and (iii) delays the onset of CDK4/6i resistance in breast cancer by driving deeper suppression of E2F targets. Our results support the clinical development of selective CDK2 inhibitors.
Journal
|
CCNE1 (Cyclin E1)
|
CCNE1 amplification
|
INX-315
over1year
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCNE1 (Cyclin E1)
|
HER-2 negative • CCNE1 amplification
|
INX-315
almost2years
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCNE1 (Cyclin E1)
|
HER-2 negative • CCNE1 amplification
|
INX-315